A comparative study on the time to achieve negative nucleic acid testing and hospital stays between danoprevir and lopinavir/ritonavir in the treatment of patients with COVID‐19

Autor: Li Wang, Xuping Peng, Xianglin Tu, Shumei Wang, Donghong Zhu, Weihua Ju, Yanxia Huang, Hongyi Chen, Huabao Sun, Zhicheng Zhang, Jianfeng Rao, Xue Li
Rok vydání: 2020
Předmět:
Cyclopropanes
Male
Lopinavir/ritonavir
Isoindoles
Nucleic Acid Testing
Severity of Illness Index
Lopinavir
0302 clinical medicine
immune system diseases
time to achieve negative nucleic acid testing
030212 general & internal medicine
Young adult
Research Articles
Sulfonamides
Danoprevir
virus diseases
Middle Aged
Drug Combinations
Infectious Diseases
Lopinavir/Ritonavir
COVID-19 Nucleic Acid Testing
Female
030211 gastroenterology & hepatology
Research Article
medicine.drug
Adult
medicine.medical_specialty
Adolescent
Proline
Coronavirus disease 2019 (COVID-19)
Lactams
Macrocyclic
Antiviral Agents
Young Adult
03 medical and health sciences
COVID‐19
Virology
Internal medicine
Severity of illness
medicine
Humans
Aged
Ritonavir
business.industry
COVID-19
Length of Stay
COVID-19 Drug Treatment
business
Zdroj: Journal of Medical Virology
ISSN: 1096-9071
0146-6615
DOI: 10.1002/jmv.26141
Popis: BackgroundIn late December 2019, the coronavirus disease 2019 (COVID-19) first outbroke in Wuhan city, China, and has now become a global pandemic. However, there is no specific antiviral treatment for COVID-19.MethodsThis study was approved by the Ethics Committee of the Ninth Hospital of Nanchang. This study enrolled 33 COVID-19 patients in the nineth hospital of Nanchang from January 27th to February 24th, 2020. Clinical indexes of patients upon admission/discharge were examined. Patients were divided into two groups according to different treatment plans (Danoprevir; Lopinavir/Ritonavir). The days to achieve negative nucleic acid testing and the days of hospital stays were counted and statistically analyzed.ResultsCOVID-19 patients treated with Danoprevir or Lopinavir/Ritonavir were all improved and discharged. Indexes like blood routine, inflammation and immune-related indexes were significantly recovered after treatment. Additionally, under the circumstance that there was no significant difference in patients’ general information between the two groups, we found that the mean time to achieve negative nucleic acid testing and hospital stays of patients treated with Danoprevir both were significantly shorter than those of patients with Lopinavir/Ritonavir.ConclusionCollectively, applying Danoprevir is a good treatment plan for COVID-19 patients.Highlight1. The average time to achieve negative nucleic acid testing of COVID-19 patients treated with Danoprevir was obviously shorter than that of patients treated with Lopinavir/Ritonavir;2. The average time of hospital stays of COVID-19 patients treated with Danoprevir was significantly shorter than that of patients treated with Lopinavir/Ritonavir.
Databáze: OpenAIRE
Externí odkaz: